telaprevir

01/01/2014 - "Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection."
01/01/2015 - "Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS. "
07/01/2013 - "Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic-pharmacodynamic relationships. "
06/01/2013 - "Study C209 evaluated the activity of telaprevir in treatment-naïve patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. "
08/01/2005 - "In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection."

07/01/2013 - "Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study."
03/26/2012 - "In in vitro studies, telaprevir shows good activity against genotype 1 HCV, including viral isolates from patients with chronic hepatitis C. "
03/01/2012 - "The examination of HCV virological clearance through several randomized clinical trials of telaprevir in genotype 1 chronic hepatitis C. "
02/01/2011 - "Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients."
01/01/2010 - "A 57-year-old woman with chronic hepatitis C was included in a phase 2 rollover study of VX-950. "

12/01/2014 - "A significantly greater proportion of patients were persistent to the 3-drug hepatitis C regimen containing telaprevir in specialty pharmacy, compared with retail pharmacy (56.0% vs. 39.9%, P  less than  0.001). "
01/01/2013 - "This article briefly reviews the properties of telaprevir and its status in the context of rapidly evolving aspects of management of chronic hepatitis C."
12/01/2014 - "Continuously eligible patients who started a new 3-drug regimen containing telaprevir were included in the study and followed for up to 12 months after the index hepatitis C claim. "
07/01/2015 - "Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C."
03/01/2015 - "Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient."

12/01/2015 - "HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. "
09/30/2013 - "The 16-week interim report of the HEP3002 trial expanded the access program to Telaprevir, enrolling patients with advanced fibrosis who fulfilled the safety criteria of registration trials only, and offered an unbiased evaluation of Telaprevir tolerability and safety in this most in-need population, since the rates of treatment discontinuation due to adverse events were up to 14%. "
01/01/2016 - "In telaprevir-treated patients, the rate of RVR was similar in patients with F0-F2, F3 and F4 fibrosis (85%, 84%, 78%, respectively), and the SVR rates among RVR patients was similar irrespective of LF. "
09/01/2015 - "We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. "
04/01/2015 - "SVR rates were 46% (95% CI: 42-50) and 60% (95% CI: 57-64) in telaprevir patients with and without cirrhosis, respectively. "

09/01/2014 - "The objectives of this study were to determine the incidence of rash in telaprevir-treated patients, its management, and the impact on sustained virological response and to identify any risk factors for rash development. "
02/01/2012 - "In telaprevir trials, approximately half of treated patients had rash. "
05/01/2016 - "The median time to onset of rash following telaprevir initiation was 25 days (range: 3-79 days). "
10/01/2015 - "After 5 days of treatment, he suffered from a telaprevir-associated skin rash on his body and four limbs. "
09/01/2014 - "Incidence and Management of Rash in Telaprevir-Treated Patients."